FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of ...

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and ...

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study used SEER 17 data, showing a steady decline in SCLC cases across ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...